High-mobility group box 1 in multiple sclerosis
| Autor: | Daniel Sternberg, David Hojnacki, Chana Kolb, Trevor Chichelli, Zohara Sternberg, Kailash C. Chadha, Neel Patel, Allison Drake, Jinhee Yu |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male 0301 basic medicine medicine.medical_specialty Multiple Sclerosis medicine.medical_treatment Immunology chemical and pharmacologic phenomena Inflammation HMGB1 Severity of Illness Index Gastroenterology RAGE (receptor) Young Adult 03 medical and health sciences 0302 clinical medicine Glycation Internal medicine Humans Medicine HMGB1 Protein Aged biology business.industry Multiple sclerosis Area under the curve Middle Aged medicine.disease 030104 developmental biology Cytokine ROC Curve Case-Control Studies biology.protein Biomarker (medicine) Female medicine.symptom business Biomarkers 030217 neurology & neurosurgery |
| Zdroj: | Immunologic Research. 64:385-391 |
| ISSN: | 1559-0755 0257-277X |
| Popis: | This study is one in series determining the potential of RAGE axis (receptor for advanced glycation end products, isoforms, ligands) as a biomarker in multiple sclerosis (MS). We evaluated serum levels of RAGE ligand, the high-mobility group box (HMGB)1 in MS patients, and assessed the correlation between HMGB1 serum levels and the use of disease-modifying drugs (DMDs), and between HMGB1 serum levels and indicators of MS disease severity. HMGB1 serum levels were compared between 96 (23 males) MS patients and 34 age- and gender-matched healthy controls (HCs) using enzyme-linked immunosorbent assays. DMD-naive MS patients had significantly higher HMGB1 serum levels compared with DMD-treated (P = 0.04) and compared with HCs (P = 0.01). HMGB1 serum levels were not significantly different between total MS patients (DMD-naive plus DMD-treated) and HCs (P = 0.09). DMD-naive MS patients in clinical relapse tended to have lower HMGB1 serum levels than clinically stable RRMS patients (P = 0.07). HMGB1 serum levels showed 0.65 area under the curve (95 % CI 0.55–0.95) sensitivity/specificity for MS clinical relapse. The role of HMGB1 in MS disease pathology and DMD modulation of this protein warrant further investigations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink